A request for FDA approval for the molnupiravir tablet to treat mild-to-moderate COVID-19 cases has been submitted by a major US pharmaceutical company.
COVID-19 treatment with a pill
An experimental pill developed by the US pharmaceutical company Merck to treat mild-to-moderate cases of COVID-19 has been approved for use in the United States under an emergency authorization request. This would add a promising new tool to the worldwide effort to combat the virus.
It was announced earlier this month that molnupiravir, a drug developed by Merck, has been demonstrated in early trials to cut coronavirus hospitalizations by 50%. The application for molnupiravir was filed to the US Food and Drug Administration (FDA) on Monday.
Efficacy Of The COVID-19 Pill
“We are working with regulatory agencies throughout the world to submit applications for emergency use or marketing authorization in the coming months,” Merck, which is known as MSD outside of the United States and Canada, said.
Robert Davis, the company’s chief executive officer, and the president said in a statement that the “exceptional impact of this epidemic requires that we move with unparalleled urgency.”
Unprecedented progress could be made by developing an antiviral pill that people can take at home to reduce their symptoms and speed up their recovery. This would relieve the overwhelming caseload in US hospitals while also assisting in preventing outbreaks in poorer countries with weaker healthcare systems.
It would also strengthen the two-pronged strategy to combating the pandemic: treatment, which would include medication, and prevention, which would consist of immunizations, among other things.
On the other hand, top US health officials continue to promote immunizations as the most effective method of protecting against COVID-19.
In a recent discussion about Merck’s medicine, Dr. Anthony Fauci stated, “It is far better to prevent yourself from becoming infected than it is to have to cure an infection.”
The Food and Drug Administration (FDA) will examine the information provided by the manufacturer regarding the drug’s safety and effectiveness before making a judgment.
In a statement, Merck and its partner Ridgeback Biotherapeutic said they explicitly requested that the FDA give emergency use authorization for persons with mild-to-moderate COVID-19 who are at risk of severe disease or hospitalization.